Current Report Filing (8-k)
14 August 2017 - 6:42PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 14, 2017
DOUGHERTY’S PHARMACY, INC.
(Exact name of registrant as specified in its
charter)
Commission File Number:
000-27945
Delaware
|
75-2900905
|
(State or other jurisdiction
|
(IRS Employer
|
of incorporation)
|
Identification No.)
|
5924 ROYAL LANE, SUITE 250
DALLAS, TEXAS 75230
(Address of principal executive offices and
Zip Code)
Registrant’s telephone number, including
area code:
972-250-0945
N/A
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240. 12b-2).
Emerging growth company
☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02 Results
of Operations and Financial Condition
On August 14, 2017, Dougherty’s Pharmacy, Inc. (the “
Company
”)
issued a press release regarding its release of second quarter results.
Item 7.01 Regulation FD Disclosure
The following information is furnished pursuant to Item 2.02, "Results
of Operations and Financial Condition" and Item 7.01, "Regulation FD Disclosure."
On August 14, 2017, the Company issued the attached press release
reporting its financial results for the second quarter of 2017. A copy of the Company’s press release is attached hereto
as Exhibit 99.1 and is hereby incorporated by reference.
Item
9.01 Financial Statements and Exhibits
(d) Exhibits.
The following exhibit
is furnished herewith:
99.1 Press
Release Dated August 14, 2017.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: August 14, 2017
|
Dougherty’s Pharmacy, Inc.
|
|
|
|
By:
|
/s/ Mark S. Heil
|
|
|
Mark S. Heil
President and Chief Financial Officer (Duly Authorized Principal
Executive Officer and Principal Financial Officer)
|